LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial. - Mabrouk OS; Tichler B; Arnold HM; Thoma EC; Alexanian SM; Chen J; Liu TY; Hirschhorn B; Llorens Arenas R; Annand JW; Kapadnis U; Shomo AA; et al. (Nature medicine, 2026)